Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more
Astria Therapeutics Inc (ATXS) - Net Assets
Latest net assets as of September 2025: $233.25 Million USD
Based on the latest financial reports, Astria Therapeutics Inc (ATXS) has net assets worth $233.25 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($271.87 Million) and total liabilities ($38.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $233.25 Million |
| % of Total Assets | 85.8% |
| Annual Growth Rate | 154.68% |
| 5-Year Change | 685.03% |
| 10-Year Change | 532.29% |
| Growth Volatility | 365137.74 |
Astria Therapeutics Inc - Net Assets Trend (2012–2024)
This chart illustrates how Astria Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Astria Therapeutics Inc (2012–2024)
The table below shows the annual net assets of Astria Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $319.26 Million | +31.32% |
| 2023-12-31 | $243.12 Million | +9.90% |
| 2022-12-31 | $221.22 Million | +80.86% |
| 2021-12-31 | $122.31 Million | +200.75% |
| 2020-12-31 | $40.67 Million | +13.85% |
| 2019-12-31 | $35.72 Million | +2.23% |
| 2018-12-31 | $34.94 Million | +196.32% |
| 2017-12-31 | $11.79 Million | -59.46% |
| 2016-12-31 | $29.09 Million | -42.40% |
| 2015-12-31 | $50.49 Million | +169.12% |
| 2014-12-31 | $-73.05 Million | -39.99% |
| 2013-12-31 | $-52.18 Million | -1217077.61% |
| 2012-12-31 | $4.29K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Astria Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 67475862200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $57.00K | 0.02% |
| Other Comprehensive Income | $163.00K | 0.05% |
| Other Components | $993.84 Million | 311.29% |
| Total Equity | $319.26 Million | 100.00% |
Astria Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Astria Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
$718.16 Million |
|
Esquire Financial Holdings Inc
NASDAQ:ESQ
|
$718.22 Million |
|
Uniqure NV
NASDAQ:QURE
|
$718.41 Million |
|
UroGen Pharma Ltd
NASDAQ:URGN
|
$718.63 Million |
|
Shenzhen Feima International Supply Chain Co Ltd
SHE:002210
|
$718.01 Million |
|
Zen Technologies Limited
NSE:ZENTEC
|
$718.01 Million |
|
Premier Investments Ltd
AU:PMV
|
$717.92 Million |
|
QI7
F:QI7
|
$717.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Astria Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 243,116,000 to 319,263,000, a change of 76,147,000 (31.3%).
- Net loss of 94,260,000 reduced equity.
- New share issuances of 152,417,000 increased equity.
- Other comprehensive income increased equity by 95,487,000.
- Other factors decreased equity by 77,497,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-94.26 Million | -29.52% |
| Share Issuances | $152.42 Million | +47.74% |
| Other Comprehensive Income | $95.49 Million | +29.91% |
| Other Changes | $-77.50 Million | -24.27% |
| Total Change | $- | 31.32% |
Book Value vs Market Value Analysis
This analysis compares Astria Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1017.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 194818.14x to 1017.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.03 | $5784.30 | x |
| 2013-12-31 | $-361.33 | $5784.30 | x |
| 2014-12-31 | $-505.83 | $5784.30 | x |
| 2015-12-31 | $376.72 | $5784.30 | x |
| 2016-12-31 | $107.53 | $5784.30 | x |
| 2017-12-31 | $32.63 | $5784.30 | x |
| 2018-12-31 | $41.48 | $5784.30 | x |
| 2019-12-31 | $19.14 | $5784.30 | x |
| 2020-12-31 | $13.30 | $5784.30 | x |
| 2021-12-31 | $13.70 | $5784.30 | x |
| 2022-12-31 | $15.13 | $5784.30 | x |
| 2023-12-31 | $8.07 | $5784.30 | x |
| 2024-12-31 | $5.68 | $5784.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Astria Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-29.52%) is above the historical average (-97.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -365.42% | 0.00% | 0.00x | 1.47x | $-16.10K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.90 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.58 Million |
| 2015 | -64.62% | 0.00% | 0.00x | 1.27x | $-37.68 Million |
| 2016 | -123.98% | 0.00% | 0.00x | 1.38x | $-38.97 Million |
| 2017 | -232.06% | -5472.80% | 0.03x | 1.52x | $-28.54 Million |
| 2018 | -74.04% | 0.00% | 0.00x | 1.12x | $-29.36 Million |
| 2019 | -73.61% | 0.00% | 0.00x | 1.17x | $-29.86 Million |
| 2020 | -91.14% | 0.00% | 0.00x | 1.17x | $-41.13 Million |
| 2021 | -159.36% | 0.00% | 0.00x | 1.04x | $-207.14 Million |
| 2022 | -22.68% | 0.00% | 0.00x | 1.04x | $-72.29 Million |
| 2023 | -29.98% | 0.00% | 0.00x | 1.05x | $-97.20 Million |
| 2024 | -29.52% | 0.00% | 0.00x | 1.07x | $-126.19 Million |
Industry Comparison
This section compares Astria Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Astria Therapeutics Inc (ATXS) | $233.25 Million | -365.42% | 0.17x | $718.13 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |